Yiling Pharmaceutical Co., Ltd. is a company whose office address is No.238 Tianshan Street, Yuhua District, Shijiazhuang City, Hebei Province, which is an enterprise in Shijiazhuang City, Hebei Province. Lianhua Qingwen Capsule/Granule, a product of Yiling Pharmaceutical Co., Ltd., has been listed as a recommended drug in the medical observation period by the Diagnostic and Therapeutic Plan for Infected Pneumonia in novel coronavirus (Trial Fifth Edition), and its indication has been COVID-19.
Under the leadership of Academician Wu Yiling, Shijiazhuang Yiling Pharmaceutical Co., Ltd. has always adhered to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leading factor, established a unique operation mode of "theory-clinical-scientific research-industry-teaching" and established an innovative technology system of new drug research and development oriented to the theoretical innovation of collateral diseases in traditional Chinese medicine.
Achievements of Yiling Pharmaceutical:
In 2022, Yiling Pharmaceutical celebrated its 30th anniversary. Yiling Pharmaceutical was born in 1992, formerly known as Huangdi Pharmaceutical Factory of Shijiazhuang Development Zone Institute of Medicine. Over the past 30 years, it has gradually become a national key high-tech enterprise, a top 500 listed companies in China, a top brand value 100 in China, and a top Chinese medicine enterprise 10 in China.
A glimpse of the whole leopard shows that the development process of Yiling Pharmaceutical from weak to strong is also the epitome of the development of Chinese medicine industry. Since 2002, the state has continuously issued policies to vigorously support the development of Chinese medicine. Under the policy dividend, the Chinese medicine industry has ushered in rapid development.